Ozone gas may ease chemo nerve pain, small trial hopes
NCT ID NCT04299893
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding ozone therapy to standard care can reduce nerve pain caused by chemotherapy. 42 adults with cancer and persistent nerve pain will receive either ozone or oxygen gas via rectal insufflation for 16 weeks. The main goal is to see if pain and quality of life improve, and whether the treatment is cost-effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ozone gas
- What this could lead to
- If it works, this could offer a new, low-cost way to reduce chronic nerve pain in cancer survivors.
- What could go wrong
- This is a small, early-phase trial with only 42 participants. The effect may be small or no better than the placebo (oxygen).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 42 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2020
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Adults \> = 18 years old. * 2\. Any kind of cancer in any stage, treated with any kind of chemotherapy, and life expectancy \> = 6 months. * 3\. Clinical diagnosis of painful chemotherapy-induced peripheral neuropathy, toxicity Grade 2 or higher according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0, for \> = 3 months and without the inclusion of new treatments for pain and/or neuropathy for \> = 1 month. * 4\. "Average pain" \> = 3/10 according to the Brief Pain Inventory-Short Form (BPI-SF) \> = 3 months beyond chemotherapy completion. * 5\. Pregnant women cannot participate in the clinical trial. * 6\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from the 14 days prior to the first ozone therapy session up to 14 days after the last one. * 7\. Patients who have signed and dated the study 's specific informed consent Exclusion Criteria: * 1\. Age \< 18 years old. * 2\. Pregnancy at the time of enrollment. * 3\. Women with childbearing potential who are unwilling to perform a pregnancy test and/or employ adequate contraception from the 14 days prior to the first ozone therapy session up to 14 days after the last one. * 4\. Clinical suspicion that peripheral neuropathy (compressive or diabetic neuropathy) in the same area prior to receiving neurotoxic chemotherapy. * 5\. Psychiatric illness or social situations that would limit compliance with study requirements. * 6\. Those who are unable to fill in the scales used to measure quality of life variables * 7\. Specific liver enzymes \[Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \> 5 times the upper limit of normal * 8\. Increased creatinine \> 3 times the upper limit of normal. * 9\. Hemodynamically or clinically unstable patients or uncontrolled severe illness. * 10\. Uncontrolled cancer disease. * 11\. Leptomeningeal carcinomatosis. * 12\. Life expectancy \< 6 months * 13\. Contraindication or disability for rectal ozone administration or to attend scheduled treatments. * 14\. Known allergy to ozone. * 15.Patients who do not meet all the inclusion criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Complejo Hospitalario Materno Insular
RECRUITINGLas Palmas de Gran Canaria, Las Palmas, 35016, Spain
-
Hospital Universitario de Gran Canaria Dr. Negrín
RECRUITINGLas Palmas de Gran Canaria, Las Palmas, 35019, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can TENS, compression, or cold therapy stop chemo nerve pain?
- Can an antidepressant calm Chemotherapy's nerve pain?
- Retraining the senses to fight chemotherapy nerve damage
- Retraining the senses to fight chemotherapy nerve damage
- Zapping the brain to fight teen pain: a new hope?
- Chilling out Chemo's side effects: could cold therapy shield nerves?